Press Release

Arthrotec in-licensing agreement with G.D.SearleDecember 8, 1998

 KAKEN has acquired development and marketing rights in Japan to Arthrotec (Diclofenac/ Cytotec combination ) from G.D. Searle & Co., 5200 Old Orchard Road, Skokie, IL, US, a pharmaceutical division of Monsanto.
 The agreement was signed on December 8, 1998. KAKEN plans to begin clinical studies of Arthrotec in Japan in the second half of 1999.

Back to list